Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Nod-like receptor function in cystic fibrosis: an investigation of novel therapeutic targets for reducing lung-damaging inflammation in cystic fibrosis
EF 2009-10
Résumé
Cystic fibrosis (CF) is the most common and deadly genetic disease affecting young Canadians. Even today, only half of the people living with CF will survive beyond their mid-30's. New treatments for CF are critically needed.
Lung disease is the major cause of disability and death in CF. People with CF are born with normal lungs, but infection and inflammation begin to cause lung damage soon after birth. At present, antibiotic treatment targets only the infectious component of CF lung disease and new treatments to target lung inflammation are predicted to substantially improve the health of those living with CF. To date, however, scientists have not been able to determine the cause of lung inflammation in CF.
Recent studies performed in the Turvey lab using the airway cells and blood from patients with CF indicate that a sophisticated immunological alarm system, the innate immune system, is the key biological mechanism contributing to lung inflammation in CF. In the proposed studies, I will perform an in-depth analysis on the role of one component of the innate immune system - Nod-like Receptors (NLRs) - in CF airway inflammation. I will also investigate whether blocking NLR function is likely to safely reduce the damaging inflammation occurring in the lungs of people with CF. This research is entirely relevant to the needs of the CF community in its aim to identify potential new treatments for life-limiting CF lung disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
201562
Name
Tang Anthony
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Nod-like receptor function in cystic fibrosis: an investigation of novel therapeutic targets for reducing lung-damaging inflammation in cystic fibrosis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cystic Fibrosis; Inflammation; Innate Immunity; Nod-Like Receptors
Abstract
Cystic fibrosis (CF) is the most common and deadly genetic disease affecting young Canadians. Even today, only half of the people living with CF will survive beyond their mid-30's. New treatments for CF are critically needed.
Lung disease is the major cause of disability and death in CF. People with CF are born with normal lungs, but infection and inflammation begin to cause lung damage soon after birth. At present, antibiotic treatment targets only the infectious component of CF lung disease and new treatments to target lung inflammation are predicted to substantially improve the health of those living with CF. To date, however, scientists have not been able to determine the cause of lung inflammation in CF.
Recent studies performed in the Turvey lab using the airway cells and blood from patients with CF indicate that a sophisticated immunological alarm system, the innate immune system, is the key biological mechanism contributing to lung inflammation in CF. In the proposed studies, I will perform an in-depth analysis on the role of one component of the innate immune system - Nod-like Receptors (NLRs) - in CF airway inflammation. I will also investigate whether blocking NLR function is likely to safely reduce the damaging inflammation occurring in the lungs of people with CF. This research is entirely relevant to the needs of the CF community in its aim to identify potential new treatments for life-limiting CF lung disease.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tang, Anthony
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~